THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES

Size: px
Start display at page:

Download "THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES"

Transcription

1 THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016

2 There is growing distrust of pharma in light of several recent and dramatic increases in drug prices in the US. Global US-based patient group specialising in diabetes in 2016, patientview is publishing 20 corporate reputation of pharma reports, analysing the results from the 1,075 patient groups responding to the 2015 survey. specialty reports: cancer I circulatory conditions I diabetes I hiv/aids I hepatitis I neurological conditions I mental health I respiratory conditions I skin conditions I rare diseases (10 reports) geographic-region reports: europe I eastern europe I germany I global I italy I latin america I nordic I spain I uk I usa (10 reports)

3 CONTENTS ABOUT THIS REPORT Page 1 WHAT DID DIABETES PATIENT GROUPS SAY ABOUT PHARMA IN 2015? Summary of the industry-wide findings (as judged by diabetes patient groups) Page 3 SOME POINTS ABOUT THE DIABETES CORPORATE RANKINGS Page 8 WHAT CAN PHARMA COMPANIES DO TO IMPROVE THEIR CORPORATE REPUTATION? Page 9 COMMENTS FROM DIABETES PATIENT GROUPS, 2015 Page 10 METHODOLOGY OF THE PATIENT-GROUP SURVEY Page 11 APPENDIX 1: Data on how diabetes patient groups see the pharmaceutical industry in 2015 Page 12 APPENDIX 2: Rankings of the 21 pharma companies for each of the six indicators of corporate reputation, as perceived by diabetes patient groups in 2015 Page 17 APPENDIX 3: Profiles of the 21 pharma companies, as perceived by diabetes patient groups in 2015 Page 26 APPENDIX 4: Profile of the 139 respondent diabetes patient groups Page 49

4 LIST OF TABLES AND CHARTS BASED ON THE VIEWS OF DIABETES PATIENT GROUPS, 2015 Percentage of diabetes patient groups claiming familiarity with the company Page 2 Percentage of diabetes patient groups claiming familiarity with the company, and which also worked with it Page 2 Percentage of patient groups of different therapy areas worldwide stating that the pharma industry had an Excellent or Good corporate reputation in 2015 ENSURING PATIENT SAFETY PATIENT CENTRICITY BEING TRANSPARENT HAVING INTEGRITY MANAGING ADVERSE NEWS ABOUT PRODUCTS PROVIDING SERVICES BEYOND THE BUSINESS REMIT Page 3 Page 5 Page 5 Page 6 Page 6 Page 7 Page 7 Diabetes patient groups can partner with many pharma companies Page 8 If a pharma company wishes to improve its corporate reputation with patients and patient groups, which single strategy from the list below do you think would be MOST IMPORTANT for the company to follow? Please select only ONE option How do you think your organisation s members (or the people you represent) would rate the corporate reputation of the following healthcare sectors in 2015? Page 9 Page 13 What do you think has happened to the corporate reputation of the pharma industry over the past five years? Page 14 How good or bad do you think the pharma industry is in 2015 at carrying out the following activities (all of which influence their corporate standing with patients and patient groups)? How good or bad do you think the pharma industry is in 2015 at carrying out the following activities (all of which influence their corporate standing with patients and patient groups)? Page 15 Page 16 Companies with the most effective patient-centred strategy (rankings of 21 companies, 2015) Page 18 Companies providing the best high-quality patient information (rankings of 21 companies, 2015) Page 19 Companies with the best record on patient safety (rankings of 21 companies, 2015) Page 20 Companies with the most-useful high-quality products (rankings of 21 companies, 2015) Page 21 Companies with the best record of transparency (rankings of 21 companies, 2015) Page 22 Companies with the best record on integrity (rankings of 21 companies, 2015) Page 23 Rankings of the 21 pharmaceutical companies in 2015, ALPHABETIC ORDER Page 24 Rankings of the 21 pharmaceutical companies in 2015, HIGHEST TO LOWEST Page 25 Profile of the 139 respondent patient groups with an interest in diabetes 2015, by country Page 50 Profile of the 139 respondent patient groups with an interest in diabetes 2015, by geographic remit Page 50

5 LIST OF TABLES AND CHARTS CONTINUED AbbVie page 28 Actavis page 29 Amgen page 30 AstraZeneca page 31 Bayer page 32 Boehringer Ingelheim page 33 B-MS page 34 Eli Lilly page 35 GSK page 36 Janssen page 37 Menarini page 38 Merck & Co (US) page 39 Novartis page 40 Novo Nordisk page 41 Pfizer page 42 Roche page 43 Sandoz page 44 Sanofi page 45 Servier page 46 Takeda page 47 Teva page 48 profiles of the 21 companies, according to the diabetes patient groups familiar with these companies, or which have worked with them Each profile contains... company background information Annual revenue (latest-available year), comprising amount in currency, as quoted by the profiled company itself. = increase in revenue over the previous year or = decrease in revenue. The profiled company s main treatment subject areas (and areas of R&D). A mission statement from the profiled company. how the company has performed at the six indicators of corporate reputation The profiled company s performance at the six indicators of corporate reputation in 2015, according to the diabetes patient groups familiar with the company. The profiled company s performance at the six indicators of corporate reputation, according to the diabetes patient groups that have worked with the company. How the profiled company performed among diabetes patient groups for different countries/regions, compared with the company s global averages for diabetes patient groups in how the company ranks for corporate reputation compared with other companies The profiled company s rankings among diabetes patient groups in 2015 for the six indicators of corporate reputation, compared with 20 other companies. The profiled company s rankings worldwide in 2015 for the six indicators of corporate reputation, compared with 47 other companies. profile of the patient groups familiar with the company Other companies that partner with a significant number of the profiled company s partner patient groups. The countries of the patient groups familiar with the profiled company. Janssen Pharmaceutical Companies of Johnson & Johnson

6 Contact details PatientView Registered office: One Fleet Place, London, EC4M 7WS, UK Tel: +44-(0) Registered in England, number: Data protection registration number: Z VAT registration number: GB Copyright 2016 PatientView Ltd. All rights reserved. This booklet is the property of PatientView, and no part may be reproduced without permission, or passed on to any third party without the permission of PatientView.

John Ansell President, John Ansell Consultancy Thame, UK

John Ansell President, John Ansell Consultancy Thame, UK Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1

More information

US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health

US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,

More information

PBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars

PBS Growth. The changing composition of the PBS. PBS Top 10 drugs in transition. Shifting sands for industry as generic volume soars PBS Growth The changing composition of the PBS PBS Top 10 drugs in transition Shifting sands for industry as generic volume soars The under co-payment market PBS Update 2014-15 Growth in PBS spending was

More information

TABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products

TABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products TABLE OF CONTENTS 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Epidemiology 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Co-morbidities and Complications 2.6 Classification

More information

Global Skin Cancer Diagnosis and Therapeutics Market Research and Forecast

Global Skin Cancer Diagnosis and Therapeutics Market Research and Forecast Report Information More information from: https://www.wiseguyreports.com/reports/3186925-global-skin-cancer-diagnosis-and-therapeuticsmarket-research Global Skin Cancer Diagnosis and Therapeutics Market

More information

Oncology Pipeline Analytics

Oncology Pipeline Analytics Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to

More information

BRIC DIABETES DRUGS MARKET

BRIC DIABETES DRUGS MARKET BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a

More information

Organ Transplantation Market Research Report- Global Forecast Till 2023

Organ Transplantation Market Research Report- Global Forecast Till 2023 Report Information More information from: https://www.marketresearchfuture.com/reports/915 Organ Transplantation Market Research Report- Global Forecast Till 2023 Report / Search Code: MRFR/HC/0410-HCRR

More information

LETTERS FOR ISSUE ON

LETTERS FOR ISSUE ON S FOR ISSUE ON 27.08.2015 NEW DRUG S. NAME OF APPLICANT DIARY TYPE OF 1. M/S. INTAS PHARMACEUTICALS LIMITED - CT NOC (2) 2. M/S. PFIZER LIMITED - QUERY 3. M/S. MSN LABORATORIES - ADDITIONAL SITE 4. M/S.

More information

CHAPTER ONE: EXECUTIVE SUMMARY

CHAPTER ONE: EXECUTIVE SUMMARY CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Total Size and Growth of the Market Issues and Trends Affecting Market Leading Competitors CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

More information

Influenza Vaccination Market Research Report Global Forecast till 2023

Influenza Vaccination Market Research Report Global Forecast till 2023 Report Information More information from: https://www.marketresearchfuture.com/reports/1621 Influenza Vaccination Market Research Report Global Forecast till 2023 Report / Search Code: MRFR/HC/1090-HCRR

More information

COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global

COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global Opportunity Analysis and Industry Forecasts, 2015-2022 COPD and

More information

THINC-it: what is it? John Harrison Alzheimer Center, VU University Medical Center, West London Mental Health Trust, Metis Cognition Ltd

THINC-it: what is it? John Harrison Alzheimer Center, VU University Medical Center, West London Mental Health Trust, Metis Cognition Ltd THINC-it: what is it? John Harrison Alzheimer Center, VU University Medical Center, West London Mental Health Trust, Metis Cognition Ltd Disclosures Associate Professor in the Alzheimer Center at the VU

More information

Pancreatic Cancer Market Research Report- Global Forecast till 2023

Pancreatic Cancer Market Research Report- Global Forecast till 2023 Report Information More information from: https://www.marketresearchfuture.com/reports/1638 Pancreatic Cancer Market Research Report- Global Forecast till 2023 Report / Search Code: MRFR/HC/1107-HCRR Publish

More information

Russian pharmaceutical market: 2016 vs Anna Ermolaeva AlphaRM General Manager

Russian pharmaceutical market: 2016 vs Anna Ermolaeva AlphaRM General Manager Russian pharmaceutical market: 2016 vs 2017 Anna Ermolaeva AlphaRM General Manager Russian pharmaceutical market volume 16 ~1,13 (trln, RUB)* & ~5,3 (bln, units) Including Food Supplements (FS), Medical

More information

CHAPTER ONE: EXECUTIVE SUMMARY

CHAPTER ONE: EXECUTIVE SUMMARY CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Size and Growth of the Market Issues and trends Leading Competitors CHAPTER TWO: INTRODUCTION AND OVERVIEW Definition of Pain Magnitude

More information

Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential Forecast to 2023

Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential Forecast to 2023 Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential Forecast to 2023 Global Psoriasis Pipeline Drugs Industry Sizing, Growth and Forecast

More information

Insights from the Kaiser Permanente database

Insights from the Kaiser Permanente database Insights from the Kaiser Permanente database Jashin J. Wu, M.D. Founding Director of Dermatology Research Director, Psoriasis Clinic Department of Dermatology Kaiser Permanente Los Angeles Medical Center

More information

Vascular Endothelial Growth Factor Inhibitor Market

Vascular Endothelial Growth Factor Inhibitor Market May 2017 Report Id : REP-GB-3292 Status : Ongoing Category : Healthcare, Pharmaceuticals & Medical Devices 2015 Future Market Insights, All Rights Reserved About Future Market Insights Future Market Insights

More information

ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS

ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS PHM119B September 2016 Anuj Pathak Project Analyst ISBN: 1-62296-345-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA

More information

2014 DTC National Advertising Awards Finalists

2014 DTC National Advertising Awards Finalists 2014 DTC National Advertising Awards Finalists All Gold, Silver, and Bronze winners will be announced at the DTC National Advertising Awards Dinner on April 23. Each therapeutic category winner from Television,

More information

REFERENCE CODE GDHC1087DFR PUBLICATION DATE JUNE 2013

REFERENCE CODE GDHC1087DFR PUBLICATION DATE JUNE 2013 REFERENCE CODE GDHC1087DFR PUBLICATION DATE JUNE 2013 Executive Summary Diovan (valsartan): Key Metrics in the Seven Major Pharmaceutical Markets* 2012 Market Sales US - Diovan 5EU - Diovan Japan - Diovan

More information

American Association for Cardiovascular and Pulmonary Rehabilitation (AACVPR)

American Association for Cardiovascular and Pulmonary Rehabilitation (AACVPR) Organizations Supporting the Preventive Health Savings Act Academy of Nutrition and Dietetics ACT The App Association Aetna Alliance for Aging Research Allscripts Alzheimer s Association Alzheimer s Impact

More information

REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013

REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013 REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013 XELJANZ (PSORIASIS) - Executive Summary Table below presents key metrics for Xeljanz (tofacitinib) in seven of the nine major pharmaceutical markets

More information

Award of Contracts without Competition December 2013

Award of Contracts without Competition December 2013 SERIVCES 2850 Open Text Opentext Web CMS Software Support 125,000.00 Business Services Organisation 2259 Lynas Cooked Pork (Lynas) 63,063.00 2703 Limavady Office Products 169,477.00 2817 Merck no 3 Nutritional

More information

(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)

(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA) Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4

More information

Current and future market dynamics overview

Current and future market dynamics overview OVERVIEW Catalyst Summary EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor key findings Related reports MARKET DEFINITION Published diabetes reports Market definition for antidiabetic drugs Forecast

More information

Orencia (Rheumatoid Arthritis)

Orencia (Rheumatoid Arthritis) Orencia (Rheumatoid Arthritis) Forecast and Market Analysis GDHC1006DFR / Published November 2012 Executive Summary Orencia: Key Metrics in Rheumatoid Arthritis Markets 2012 Orencia Sales Total 7 MM $831m

More information

Industry Relationships and Institutional Affiliations

Industry Relationships and Institutional Affiliations Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study Christopher

More information

GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS

GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS HLC029D January 2013 Paul Evers Project Analyst ISBN: 0-89336-238-7 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301

More information

REFERENCE CODE GDHC1033FPR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - CURRENT AND FUTURE PLAYERS

REFERENCE CODE GDHC1033FPR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - CURRENT AND FUTURE PLAYERS REFERENCE CODE GDHC1033FPR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - CURRENT AND FUTURE PLAYERS Executive Summary Sales for Parkinson s Disease Market The Parkinson s disease market in the US,

More information

Boston University Expert Review Meeting on the Evaluation of Novartis Access

Boston University Expert Review Meeting on the Evaluation of Novartis Access Boston University Expert Review Meeting on the Evaluation of Novartis Access Principal Investigator: Richard Laing Co-investigators: Peter Rockers, Veronika Wirtz, Taryn Vian, Monica Onyango, Paul Ashigbie

More information

Supporting patient groups: a pharmaceutical company perspective Susanna Leto di Priolo Novartis Oncology Region Europe

Supporting patient groups: a pharmaceutical company perspective Susanna Leto di Priolo Novartis Oncology Region Europe Supporting patient groups: a pharmaceutical company perspective Susanna Leto di Priolo Novartis Oncology Region Europe Why pharmaceutical companies collaborate with patient groups Challenges Position on

More information

MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS. PHM154A September Anand Gijare Project Analyst ISBN:

MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS. PHM154A September Anand Gijare Project Analyst ISBN: MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS PHM154A September 2013 Anand Gijare Project Analyst ISBN: 1-56965-544-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 866-285-7215, 781-489-7301

More information

75th AAD Annual Meeting

75th AAD Annual Meeting 75th AAD Annual Meeting Poster nº 4873 A phase 3 randomized, double-blind, trial comparing the efficacy and safety of the fixed combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0.064%

More information

REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Gardasil: Key Metrics in Nine Major

More information

in patients with diabetes, nephropathy and/or chronic kidney disease Summary of recommendations July 2017

in patients with diabetes, nephropathy and/or chronic kidney disease Summary of recommendations July 2017 Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and reninangiotensin-aldosterone system blockade in patients with diabetes, nephropathy

More information

JAK AND PI3K SIGNALING PATHWAY MARKETS

JAK AND PI3K SIGNALING PATHWAY MARKETS JAK AND PI3K SIGNALING PATHWAY MARKETS PHM168A April 2014 Shalini Shahani Dewan Project Analyst ISBN: 1-56965-793-9 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free

More information

REGISTER OF INTERESTS SIGN guideline 154: Pharmacological management of glycaemic control in people with type 2 diabetes Published: 29 November 2017

REGISTER OF INTERESTS SIGN guideline 154: Pharmacological management of glycaemic control in people with type 2 diabetes Published: 29 November 2017 CHAIR John Petrie, Professor of Diabetic Medicine Financial Non-financial Non-personal Last updated Specific Non-Specific Specific Non- Specific Professor of Diabetic Medicine, University of Glasgow Academic.

More information

REFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) Executive Summary Nimenrix: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US 5EU Japan

More information

REFERENCE CODE GDHC1062CFR PUBLICATION DATE JUNE 2013 CHRONIC HEART FAILURE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC1062CFR PUBLICATION DATE JUNE 2013 CHRONIC HEART FAILURE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC1062CFR PUBLICATION DATE JUNE 2013 CHRONIC HEART FAILURE - JAPAN DRUG Executive Summary Sales for Chronic Heart Failure in the Japan The Japan Chronic heart failure (CHF) therapeutics

More information

Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( )

Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( ) Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) By Region- North America, Europe, APAC and RoW By Country - United

More information

INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS

INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS PHM162A February 2015 Kim Lawson Project Analyst ISBN: 1-62296-047-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA

More information

DIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC)

DIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC) DIABETES CARE DEVICES MARKET IN BRAZIL, RUSSIA, INDIA & CHINA (BRIC) R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p

More information

CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...

CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW... CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 MARKET ANALYSES AND FORECASTS... 2 INTENDED AUDIENCE... 2 INFORMATION SOURCES... 2 ANALYST

More information

Presenter Disclosure

Presenter Disclosure Presenter Disclosure Linong Ji.M.D Consulting and lecture fee Eli Lilly, Bristol-Myers Squibb, Novartis, Novo Nordisk, Merck, Bayer, Takeda, Sanofi-Aventis, GlaxoSmithKline, Roche, Johnson & Johnson, boehinger

More information

Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5

Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5 Characterization of Disease Burden, Comorbidities and Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo

More information

Europe Ginseng Market Report 2016

Europe Ginseng Market Report 2016 Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Europe Ginseng Market Report 2016 Europe Ginseng Market Report 2016 Publication ID: QYR12167206 Publication December

More information

Diabetic Retinopathy Treatment - Global Market Outlook ( )

Diabetic Retinopathy Treatment - Global Market Outlook ( ) Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Diabetic Retinopathy Treatment - Global Market Outlook (2015-2022) Diabetic Retinopathy Treatment - Global Market

More information

Quality of medicines in Portugal: a retrospective review of medicine recalls ( ) Ana Teresa Reis Bruna Berardo Rui Loureiro

Quality of medicines in Portugal: a retrospective review of medicine recalls ( ) Ana Teresa Reis Bruna Berardo Rui Loureiro Quality of medicines in Portugal: a retrospective review of medicine recalls (2005-2015) Ana Teresa Reis Bruna Berardo Rui Loureiro Introduction Human medicines Cosmetics Veterinary medicines Medical devices

More information

Target Audience. approach this patient case scenario, including identifying an

Target Audience. approach this patient case scenario, including identifying an Activity Overview In this case-based webcast, meet LaWanda, a 57-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 8.4%, she is currently taking basal insulin and fast-acting insulin,

More information

SUPPLEMENTARY DATA. Telediab Study Group :

SUPPLEMENTARY DATA. Telediab Study Group : Telediab Study Group : Guillaume Charpentier, MD, Department of Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France Centre d Études et de Recherches pour l Intensification du Traitement du Diabète

More information

Kenneth Gordon, 1 Kim A. Papp, 2 Kara Creamer Rice, 3 Mona Trivedi, 3 David H. Collier, 3 Greg Kricorian 3

Kenneth Gordon, 1 Kim A. Papp, 2 Kara Creamer Rice, 3 Mona Trivedi, 3 David H. Collier, 3 Greg Kricorian 3 American Academy of Dermatology 75 th Annual Meeting, Orlando, FL; March 3 7, 2017 Poster 4563 Novel Evaluation of Psoriasis Area and Severity Index (PASI) Data: Distribution of PASI Improvements in a

More information

Cardiac Monitoring: Market and Outsourcing Dynamics. October, 2014

Cardiac Monitoring: Market and Outsourcing Dynamics. October, 2014 Cardiac Monitoring: Market and Outsourcing Dynamics October, 2014 Introduction act with confidence Table of Contents Copyright and usage guidelines... 4 Introduction...5 Differentiating dedicated cardiac

More information

Actemra (Rheumatoid Arthritis)

Actemra (Rheumatoid Arthritis) Actemra (Rheumatoid Arthritis) Forecast and Market Analysis GDHC1007DFR / Published November 2012 Executive Summary Actemra: Key Metrics in Rheumatoid Arthritis Markets 2012 Actemra Sales Total 7 MM $355m

More information

GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES

GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES GLOBAL MARKETS FOR TREATMENT AND DIAGNOSIS OF SEXUALLY TRANSMITTED DISEASES PHM005C January 2013 Peggy Lehr Project Analyst ISBN: 0-89336-646-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481

More information

REFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013

REFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013 REFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013 BRODALUMAB (PSORIASIS) - Executive Summary Table below presents key metrics for brodalumab in seven of the nine major pharmaceutical markets covered

More information

REFERENCE CODE GDHCER PUBLICAT ION DATE M AY 2015 GLAUCOMA EPIDEMIOLOGY FORECAST TO 2023

REFERENCE CODE GDHCER PUBLICAT ION DATE M AY 2015 GLAUCOMA EPIDEMIOLOGY FORECAST TO 2023 REFERENCE CODE GDHCER081-15 PUBLICAT ION DATE M AY 2015 GLAUCOMA Executive Summary Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye s optic nerve, resulting in progressive,

More information

nephropathy and/or chronic kidney disease Summary of recommendations

nephropathy and/or chronic kidney disease Summary of recommendations July 2017 Guidelines: Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and reninangiotensin-aldosterone system blockade in patients

More information

Evidence grades for the recommendations

Evidence grades for the recommendations Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy

More information

Boehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence

Boehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence Boehringer Ingelheim BioXcellence Producing Value Global Contract Manufacturing Excellence Your World Class Contract Manufacturer Boehringer Ingelheim BioXcellence Producing Value Boehringer Ingelheim

More information

HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse

HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse HIV Drug Market by Medication class (multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs),

More information

taking at (Jan. 21, 2016) by Older 2016.pdf).

taking at (Jan. 21, 2016) by Older 2016.pdf). HSGAC MINORITY STAFF REPORT MANUFACTURED CRISIS How Devastating Drug Increases Are Harming America s Seniors U.S. Senate Homeland Security & Governmental Affairs Committee, Minority Office Page 1 EXECUTIVE

More information

Du gusts is megl che one. Edoardo Mannucci

Du gusts is megl che one. Edoardo Mannucci Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli

More information

MS Trust Comments on the ACD

MS Trust Comments on the ACD MS Trust Comments on the ACD Name xxxxxxxxxxx Role other Other role xxxxxxxxxxxxxxxxxx Location England Conflict no Notes Comments on individual sections of the ACD: Section 1 The MS Trust maintains that

More information

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical

More information

THYROID HORMONE THERAPY TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR

THYROID HORMONE THERAPY TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 1 SCOPE OF REPORT... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ANALYST S CREDENTIALS...

More information

RESOLUCIÓN N DE LA ONU SOBRE EL PAPEL DE LA ATENCIÓN N PRIMARIA EN LAS ENFERMEDADES CRÓNICAS

RESOLUCIÓN N DE LA ONU SOBRE EL PAPEL DE LA ATENCIÓN N PRIMARIA EN LAS ENFERMEDADES CRÓNICAS RESOLUCIÓN N DE LA ONU SOBRE EL PAPEL DE LA ATENCIÓN N PRIMARIA EN LAS ENFERMEDADES CRÓNICAS IV Congreso Nacional de Atención Sanitaria al Paciente Crónico 9 de Marzo de 2012 Alicante, Spain Richard G.

More information

SUNY Binghamton, B.S. Biochemistry, 5/80 SUNY Downstate Medical Center, M.D., 6/84

SUNY Binghamton, B.S. Biochemistry, 5/80 SUNY Downstate Medical Center, M.D., 6/84 CURRICULUM VITAE RUSSELL D'AMBRA, M.D. July 2014 North Shore Diabetes & Endocrine Associates 3003 New Hyde Park Road Suite 201 New Hyde Park, New York 11042 516-327-0850 EDUCATION: POST-GRADUATE TRAINING:

More information

Clinical Trials. Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany

Clinical Trials. Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany Clinical Trials Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany Conflict of Interest Statement German Research Council German Ministry

More information

China Oral Hypoglyceimic Agents (OHAs) Industry Report, Feb. 2011

China Oral Hypoglyceimic Agents (OHAs) Industry Report, Feb. 2011 China Oral Hypoglyceimic Agents (OHAs) Industry Report, 2010 Feb. 2011 This report Analyzes the status quo and prospect of Chinese OHAS Market. Related Products China Interventional Cardiovascular Device

More information

Clinical impact of practice registers in Bourgogne and Rhône Alpes

Clinical impact of practice registers in Bourgogne and Rhône Alpes Clinical impact of practice registers in Bourgogne and Rhône Alpes Dr Yannick Béjot The Dijon Stroke Registry EA4184, University Hospital and Medical School of Dijon, France Dr Carlos El KHOURY c.elkhoury@ch-vienne.fr

More information

REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Stivarga for colorectal cancer (CRC) in the eight major

More information

REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023

REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023 REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Vectibix for colorectal cancer (CRC) in the eight major

More information

Quality Medical Donations

Quality Medical Donations PQMD members played an active role in relief efforts following devastating floods left by Hurricane s Harvey, Irma, and Maria. PQMD Community of Practice: Connect Convene - Catalyze Are you an engaged

More information

Kaletra (HIV) Forecast and Market Analysis to GDHC1051DFR/ Published January 2013

Kaletra (HIV) Forecast and Market Analysis to GDHC1051DFR/ Published January 2013 Kaletra (HIV) Forecast and Market Analysis to 2022 GDHC1051DFR/ Published January 2013 Executive Summary Kaletra Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US - Kaletra 5EU

More information

Rituxan (Rheumatoid Arthritis)

Rituxan (Rheumatoid Arthritis) Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis GDHC1008DFR / Published November 2012 Executive Summary Rituxan: Key Metrics in Rheumatoid Arthritis Markets 2012 Rituxan Sales Total 7 MM $835m

More information

Abstract Background: Methods: Results: Conclusion:

Abstract Background: Methods: Results: Conclusion: 1131 Efficacy of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Palmoplantar Psoriasis in Patients With Moderate to Severe Plaque Psoriasis in Phase 2 and Phase 3 (ESTEEM) Trials Robert Bissonnette,

More information

Save Up To $125 with Early Bird Rates through August 21!

Save Up To $125 with Early Bird Rates through August 21! Save Up To $125 with Early Bird Rates through August 21! Experience BIG IDEAS, KEY STRATEGIES, and PRACTICAL TAKEAWAYS that will help transform how you deliver patient care! REGISTER TODAY! accc-cancer.org/oncologyconference

More information

This is a repository copy of New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: process and challenges faced.

This is a repository copy of New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: process and challenges faced. This is a repository copy of New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: process and challenges faced. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/102808/

More information

REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - Executive Summary Menomune: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US 5EU

More information

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015 Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015 Cognitive Impairment Associated

More information

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels Bertrand Cariou, 1 Maja Bujas-Bobanovic, 2 Michael J Louie,

More information

Visceral Pain Market Share, Size, Analysis, Growth, Industry Trends and Forecasts to 2024 Hexa Research

Visceral Pain Market Share, Size, Analysis, Growth, Industry Trends and Forecasts to 2024 Hexa Research Visceral Pain Market Share, Size, Analysis, Growth, Industry Trends and Forecasts to 2024 Hexa Research The global visceral pain market size was estimated at USD 9.51 billion in 2016 and is expected to

More information

Global Coverage. Regional Coverage. Company Coverage. Country Coverage. Global Coverage Regional Coverage Country Coverage

Global Coverage. Regional Coverage. Company Coverage. Country Coverage. Global Coverage Regional Coverage Country Coverage Global Influenza Drugs and Vaccines Market By Drugs (Zanamivir, Oseltamivir Phosphate, Peramivir), By Vaccine (Trivalent, Quadrivalent): Analysis By Region, By Country: Opportunities and Forecast (2016-2021)

More information

Vaccine Technologies and Global Markets

Vaccine Technologies and Global Markets A BCC Research Pharmaceutical Report and Global Markets PHM014D Use this report to: Learn about the strengths and weaknesses of each category of human and veterinary vaccine to prevent or treat infectious

More information

Molecular Diagnostics Market Share, Size, Analysis, Growth, Trends and Forecasts, 2016 to 2024 Hexa Research

Molecular Diagnostics Market Share, Size, Analysis, Growth, Trends and Forecasts, 2016 to 2024 Hexa Research Molecular Diagnostics Market Share, Size, Analysis, Growth, Trends and Forecasts, 2016 to 2024 Hexa Research " Projected to grow at a CAGR of almost 9% from 2016 to 2024, the molecular diagnostics market

More information

Boehringer Ingelheim and investment in R&D. Volker Barkmann

Boehringer Ingelheim and investment in R&D. Volker Barkmann Boehringer Ingelheim and investment in R&D Volker Barkmann I. Our Corporation Boehringer Ingelheim in brief Boehringer Ingelheim Center Our headquarters in Ingelheim, Germany Family-owned global corporation

More information

Chronic illness is a growing market for Novo Nordisk

Chronic illness is a growing market for Novo Nordisk Chronic illness is a growing market for Novo Nordisk Aslam Dalvi - Associate Portfolio Manager Denmark-based global healthcare company Novo Nordisk traces its origins to the first pioneers in insulin production

More information

Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles

Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles Antifungal Drugs Market by Drug Type [Echinocandins {Caspofungin, Micafungin, Anidulafungin and Others}, Azoles {Imidazoles, Voricanazole, Thiazoles and Others}, Polyenes {Amphotericin B, Candicidin, Hamycin,

More information

Adherence to therapy. Kamlesh Khunti University of Leicester, UK. William Polonsky University of California San Diego, USA

Adherence to therapy. Kamlesh Khunti University of Leicester, UK. William Polonsky University of California San Diego, USA Adherence to therapy Kamlesh Khunti University of Leicester, UK William Polonsky University of California San Diego, USA 1 Dualities of interest Kamlesh Khunti: Honoraria for speaking, advising or research

More information

Stroke and Headache Headache and Stroke

Stroke and Headache Headache and Stroke Stroke and Headache Headache and Stroke Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Tobias Kurth Institute of Public Health Charité Universitätsmedizin Berlin

More information

TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF

TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED

More information

REFERENCE CODE GDHCER043 PUBLICAT ION DATE NOVEMBER 2013 PARKINSON S DISEASE - EPIDEMIOLOGY FORECAST TO 2022

REFERENCE CODE GDHCER043 PUBLICAT ION DATE NOVEMBER 2013 PARKINSON S DISEASE - EPIDEMIOLOGY FORECAST TO 2022 REFERENCE CODE GDHCER043 PUBLICAT ION DATE NOVEMBER 2013 Executive Summary Parkinson s disease is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer s

More information

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn Letter Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, openlabel study J. Rosenstock 1,2,

More information

Emergency Response The People Perspective

Emergency Response The People Perspective Emergency Response The People Perspective Abigail Pollard Managing Director Blake Emergency Services 5 th March 2015 Incidents have a dramatic effect on people Internet Library How a company responds and

More information

2017 ICF GLOBAL CONSUMER AWARENESS STUDY

2017 ICF GLOBAL CONSUMER AWARENESS STUDY 2017 ICF GLOBAL CONSUMER AWARENESS STUDY EXECUTIVE SUMMARY 2017 ICF Global Consumer Awareness Study: Executive Summary 1 2017 ICF GLOBAL CONSUMER AWARENESS STUDY EXECUTIVE SUMMARY Contents 03 Introduction

More information

AFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY

AFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY AFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY Maximilian J. Hochmair, 1 Alessandro Morabito, 2 Desiree Hao, 3 Cheng-Ta Yang, 4 Ross A.

More information

THE VALUE OF TREATMENT FOR BRAIN DISORDERS A NEW VISION IN PROGRESS...

THE VALUE OF TREATMENT FOR BRAIN DISORDERS A NEW VISION IN PROGRESS... V T THE VALUE OF TREATMENT FOR BRAIN DISORDERS A NEW VISION IN PROGRESS... BRIEF DESCRIPTION The European Brain Council (EBC) is carrying out a new research project for 2015-2017 on The value of treatment

More information

A Clinical Context Report

A Clinical Context Report Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and

More information